Native Meta creative and exact outbound link observed October 22, 2026. Redirects were followed to the captured public destination. Actual GLP-1 acquisition creative; peptide/sermorelin keyword searches showed no matches. Advertiser claims are source material; activity does not establish performance. No personal, health or payment details were entered.

A long care page develops a direct offer through product quality, treatment comparisons, care steps, customer stories and assessment entry. Compare the creative with the destination and explore the other ads sharing this route.
Selected for its design and offer structure. Ad performance isn’t available in this collection.
The hook quotes the category back to itself: the headline points out that every GLP-1 ad claims $99 a month, which is something a shopper in this market has seen many times. That turns the viewer's own skepticism into the opening, so Eden gets to be the brand that agrees with them. The row of vials with different price tags shows the gap between the advertised price and what people pay, and the Eden line at the bottom gives the answer in one short sentence. Eden ran several versions of this creative from September 7, 2026.
The chart is dense for a phone screen: four vials, four small price labels and a sub-headline compete with the Eden line, and the numbers are hard to read at feed size. The point of the ad is the contrast, so the contrast has to be readable in a second. Cut it to two columns (what you see in other ads versus what Eden charges) and make Eden's $99 the biggest text on the card. Adding the lifetime price guarantee from the landing page as the final line would also answer the obvious follow-up: will my price go up?
It names a claim the viewer has already seen, which earns attention from people who've stopped trusting it.
It makes the difference between advertised and real prices visible without a paragraph of explanation.
It delivers the answer to the problem the headline raised, in the same short format.
$99 a dose, presented as the price that actually stays $99, with pay-as-you-go billing and no hidden fees.
The ad lands on Eden's GLP-1 affiliate page, a focused landing page whose hero opens on GLP-1s, finally done right and lists semaglutide at $99/mo and tirzepatide at $129/mo under monthly pricing at every dose. That label is the direct answer to this ad's complaint about prices that change, so the message carries over cleanly. The ticker under the hero adds a lifetime price guarantee, and the treatment comparison section further down gives the visitor room to check the claim. The free assessment button is the single next step.
Eden's GLP-1 affiliate page is a long, focused landing page that opens on semaglutide at $99/mo and tirzepatide at $129/mo with a free assessment, then covers quality, treatment, care steps, stories and FAQs. All 16 Eden ads in the Fluid library link here, mostly price comparisons plus creator and doctor videos.
The headline, three benefits, both monthly prices and the free assessment button answer what it costs and how to start, with Trustpilot and member-count proof alongside.
It covers where the medication comes from and who oversees care, answering whether a low price means cutting corners.
It explains the problem and how the treatment is meant to work, answering why someone would consider it at all.
It compares treatment options so the visitor can work out which one fits before starting the assessment.
It walks through the steps from assessment to ongoing care, answering what happens after the click.
It shows stories from customers, answering whether people like the visitor have used the service.
It lists what the plan includes and repeats the assessment entry, answering what the monthly price covers right before asking again.
It handles remaining questions and the safety and compounding disclosures, answering the last objections before signing up.
Read the full breakdown of this page
One of 16 Eden ads in the Fluid Inspiration Library, captured from the Meta Ad Library on Oct 22, 2026. We record that an ad ran publicly, not how it performed.